<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="or Non�?commissioned): Formal Systematic Review (Commissioned or Non�?commissioned) Nanoparticles in" exact="influenza" post="subunit vaccine development: Immunogenicity enhancement KHALAJ�?HEDAYATI et al. Khalaj�?HedayatiAtin1ChuaCaroline"/>
 <result pre="work is properly cited.file:IRV-14-92.pdf Abstract Abstract The threat of novel" exact="influenza" post="infections has sparked research efforts to develop subunit vaccines"/>
 <result pre="and types of nanoparticles (NPs) used in the preparation of" exact="influenza" post="subunit vaccine candidates to enhance humoral and cellular immune"/>
 <result pre="vaccine candidates to enhance humoral and cellular immune responses. immunogenicity" exact="influenza" post="vaccine nanoparticles subunit vaccine vaccine delivery Funding Taylor's Internal"/>
 <result pre="fig-count: table-count: page-count: word-count: Khalaj�?HedayatiA, ChuaCLL, SmookerP, LeeKW. Nanoparticles in" exact="influenza" post="subunit vaccine development: Immunogenicity enhancement. Influenza Other Respi Viruses."/>
 <result pre="650,000 deaths.1 Vaccination is the most effective method to prevent" exact="influenza" post="infection. Current influenza vaccines mainly rely on hemagglutinin (HA)"/>
 <result pre="is the most effective method to prevent influenza infection. Current" exact="influenza" post="vaccines mainly rely on hemagglutinin (HA) proteins as antigens"/>
 <result pre="These antibodies are mostly targeting the immunodominant epitopes of the" exact="influenza" post="virus that are highly variable between different virus strains."/>
 <result pre="variable between different virus strains. Each year, new variants of" exact="influenza" post="virus may emerge due to antigenic drift, which necessitates"/>
 <result pre="emerge due to antigenic drift, which necessitates the reformulation of" exact="influenza" post="vaccines on a yearly basis.2 Previously, mismatches between predicted"/>
 <result pre="cases.3 A &quot;universal�? vaccine that targets the conserved regions of" exact="influenza" post="viruses and induces a broadly protective immunity may dramatically"/>
 <result pre="protective immunity may dramatically improve protection against seasonal and pandemic" exact="influenza" post="viruses. Antibodies that target conserved sites in the HA"/>
 <result pre="and shown to confer protection in animals challenged with various" exact="influenza" post="virus strains and subtypes.4 However, it is noteworthy that"/>
 <result pre="given sufficient consideration during universal vaccine design and evaluation.5 Licensed" exact="influenza" post="vaccines are currently available as inactivated (whole inactivated virus"/>
 <result pre="boost immunogenicity. Adjuvants are particularly important in the development of" exact="influenza" post="vaccines for the elderly population who has decreased immune"/>
 <result pre="adjuvants are also required in the development of novel peptide�?based" exact="influenza" post="vaccines, which are known to have low immunogenicity. There"/>
 <result pre="six types of adjuvants that have been included in licensed" exact="influenza" post="vaccines; alum, AS03, AF03, MF59, heat labile enterotoxin, and"/>
 <result pre="virosome, which is a nanoparticle (NP). Table 1 Currently available" exact="influenza" post="vaccines for the 2019�?2020 influenza season in the United"/>
 <result pre="(NP). Table 1 Currently available influenza vaccines for the 2019�?2020" exact="influenza" post="season in the United States112 Vaccines Manufacturers Production Preparation"/>
 <result pre="their ability to deliver antigens and increase immune responses against" exact="influenza" post="antigens in vaccines. The current review focuses on the"/>
 <result pre="latest scientific advancement in the application of different NPs in" exact="influenza" post="subunit vaccine development to enhance immunogenicity (Table 2). Table"/>
 <result pre="enhance immunogenicity (Table 2). Table 2 Current development of nanoparticle�?based" exact="influenza" post="vaccines NPs Vaccine candidate composition Humoral response Cellular response"/>
 <result pre="N/A √ √ Mice Pre�?clinical 114 Recombinant A (H1N1) 2009" exact="influenza" post="VLP vaccine (HA) √ N/A N/A N/A Human Phase"/>
 <result pre="primary antigen�?presenting cells (APCs).17, 18 For efficient protection against influenza," exact="influenza" post="vaccines are required to induce specific antibody responses, such"/>
 <result pre="types of NPs have been employed in the design of" exact="influenza" post="subunit vaccines such as bacterial spores, virus�?like particles (VLPs),"/>
 <result pre="spores have been used in the design of an oral" exact="influenza" post="vaccine, where the spore coat protein of B subtilis"/>
 <result pre="the ectodomain of M2 protein, a proton channel of the" exact="influenza" post="virus, that is highly conserved across all human influenza"/>
 <result pre="the influenza virus, that is highly conserved across all human" exact="influenza" post="virus A strains, thus making it one of the"/>
 <result pre="thus making it one of the main targets for universal" exact="influenza" post="vaccine development. The authors reported that M2e was successfully"/>
 <result pre="responses. When immunized mice were further challenged with A/PR/8/34 (H1N1)" exact="influenza" post="virus, lung specimens revealed significantly lower levels of the"/>
 <result pre="in vaccine production due to their ability in binding to" exact="influenza" post="virions. In a previous study, mice that were intranasally"/>
 <result pre="Particularly interesting was the observation that in the absence of" exact="influenza" post="antigens, the killed spores alone were able to confer"/>
 <result pre="human papillomavirus (HPV) and the third generation Sci�?B�?Vac™ vaccine against" exact="hepatitis" post="B virus (HBV). VLP�?based approaches are also explored as"/>
 <result pre="as a promising approach for the development of a universal" exact="influenza" post="vaccine.37 To design a successful VLP�?based vaccine, the most"/>
 <result pre="particle�?based vaccines have been widely explored in the design of" exact="influenza" post="vaccines, with promising results in providing protection against the"/>
 <result pre="with promising results in providing protection against the infection. An" exact="influenza" post="VLP�?based vaccine candidate consisting of influenza HA, NA, and"/>
 <result pre="against the infection. An influenza VLP�?based vaccine candidate consisting of" exact="influenza" post="HA, NA, and matrix protein (M1) (H7N9 A/Shanghai/2/2013) was"/>
 <result pre="a lethal dose of H7N9 virus.38 Another study reported that" exact="influenza" post="H3N2�?VLPs expressing HA, NA, and M1 proteins induced protective"/>
 <result pre="tandem repeat of five M2e variants from human, swine, and" exact="avian influenza" post="A viruses. It was shown to protect infected mice"/>
 <result pre="repeat of five M2e variants from human, swine, and avian" exact="influenza" post="A viruses. It was shown to protect infected mice"/>
 <result pre="to protect infected mice against a lethal challenge from distinct" exact="influenza" post="A viruses (H3N2 and H5N1).40, 41 Additionally, M2e5x was"/>
 <result pre="and promote cross�?protection when tested in ferrets.42 Tandiflu1 is an" exact="influenza" post="VLP�?based vaccine candidate comprising of a hepatitis B virus"/>
 <result pre="Tandiflu1 is an influenza VLP�?based vaccine candidate comprising of a" exact="hepatitis" post="B virus core (HBc) VLPs fused to four conserved"/>
 <result pre="protective antibodies, which resulted in 100% protection from a lethal" exact="influenza" post="challenge with H1N1 in mice. In addition, serum transfer"/>
 <result pre="result in broad protection. Mice vaccinated with a mixture of" exact="influenza" post="VLPs containing 4 different HA subtypes of influenza A"/>
 <result pre="mixture of influenza VLPs containing 4 different HA subtypes of" exact="influenza" post="A viruses (H1, H3, H5, and H7) were protected"/>
 <result pre="that were not included in the vaccine.45 A few VLP" exact="influenza" post="vaccines have been tested in humans with promising results."/>
 <result pre="in humans with promising results. For example, VLP vaccines against" exact="influenza" post="A/California/04/2009 (H1N1) was tested in adults and showed good"/>
 <result pre="achieved ≥40 hemagglutinin inhibition (HAI) titer.46 For the recombinant VLP" exact="influenza" post="A (H7N9) vaccine, the presence of ISCOMATRIX™ adjuvant was"/>
 <result pre="the effect of adding a modified Salmonella flagellin protein to" exact="influenza" post="VLPs associated with HA and M1 proteins. They reported"/>
 <result pre="in a group of elderly population (≥65 years old).48 Another" exact="influenza" post="vaccine, STF2.4 × M2e (VAX102), which consists of Salmonella"/>
 <result pre="can be taken up by DCs as efficiently as the" exact="influenza" post="virus.53 Bacteriophage VLP systems employ phage capsid proteins to"/>
 <result pre="56 Several phages have been developed as antigen adjuvant for" exact="influenza" post="vaccine development. A previous study incorporated influenza conserved nucleoprotein"/>
 <result pre="antigen adjuvant for influenza vaccine development. A previous study incorporated" exact="influenza" post="conserved nucleoprotein (NP) into bacteriophage P22 through genetic engineering"/>
 <result pre="The vaccine candidate protected mice against both H1N1 and H3N2" exact="influenza" post="strains that were administered via intranasal challenge.57 Two previous"/>
 <result pre="completely protected the mice against a lethal challenge with the" exact="influenza" post="virus PR8.60 An example of bacteriophage VLPs that have"/>
 <result pre="responses.66, 67, 68 Chitosan NPs have been previously used in" exact="influenza" post="DNA vaccines and shown to exhibit high stability and"/>
 <result pre="rate that need to be considered before being used in" exact="influenza" post="subunit vaccine development.69 Alternatively, water�?soluble trimethyl chitosan and alginate"/>
 <result pre="preparation. When these materials were used to package whole inactivated" exact="influenza" post="virus and administered as vaccines, high IgG titers were"/>
 <result pre="against lethal viral challenges for a cationic liposome�?DNA complex (CLDC)�?adjuvanted" exact="influenza" post="vaccine candidate compared to un�?adjuvanted formulation.74, 75 A similar"/>
 <result pre="Fluzone/CLDC�?vaccinated animals had lower virus replication when challenged with H1N1" exact="influenza" post="viruses.76 In another study, vaccination with liposomes containing HA"/>
 <result pre="study, vaccination with liposomes containing HA and NA from various" exact="influenza" post="strains and IL�?2/GM�?CSF as an adjuvant (INFLUSOME�?VAC) resulted in"/>
 <result pre="HAI titers compared to the control groups that received commercial" exact="influenza" post="vaccines.77 Studies have shown that the dose of liposomes"/>
 <result pre="when used at a high dose (900 µg) with trivalent" exact="influenza" post="vaccine (TIV), while at 30 µg of Vaxfectin, antibody"/>
 <result pre="lower doses.71, 79 This immune�?modulatory property can be explored in" exact="influenza" post="vaccine development to produce the required immune responses just"/>
 <result pre="a virosome/DNA vaccine complex (consisting of NP�?encoding plasmid attached to" exact="influenza" post="virosomes) was reported to induce comparable T�?cell responses in"/>
 <result pre="all age�?groups, is an example of a commercially available virosome�?based" exact="influenza" post="vaccine.87 Immune�?stimulating complexes Immune�?stimulating complexes (ISCOMs) are particulate adjuvant"/>
 <result pre="in the vaccine preparation.92, 93 The use of ISCOM containing" exact="influenza" post="viral proteins has been reported to enhance the CD8+"/>
 <result pre="T cells.97 Furthermore, this vaccine elicited protection against highly pathogenic" exact="avian influenza" post="A (H5N1) virus challenge in pre�?clinical murine studies.98, 99"/>
 <result pre="cells.97 Furthermore, this vaccine elicited protection against highly pathogenic avian" exact="influenza" post="A (H5N1) virus challenge in pre�?clinical murine studies.98, 99"/>
 <result pre="100% survival rate in mice that were lethally challenged with" exact="influenza" post="A/PR/8/34 (H1N1).103 The immunogenicity of these NPs can be"/>
 <result pre="of AuNPs�?FliC improved mucosal B�?cell responses, as characterized by elevated" exact="influenza" post="specific IgA and IgG levels in nasal, tracheal, and"/>
 <result pre="There is great potential in the use of NPs in" exact="influenza" post="vaccine development as they can be used to deliver"/>
 <result pre="understanding on these issues, a safer, highly immunogenic and affordable" exact="influenza" post="vaccine can be expected in the near future. AUTHOR"/>
 <result pre="et al. Vaccine�?induced anti�?HA2 antibodies promote virus fusion and enhance" exact="influenza" post="virus respiratory disease. Sci Transl Med. 2013;5(200):200ra114. 6ZhouF, TrieuM�?C,"/>
 <result pre="Vaccine�?induced anti�?HA2 antibodies promote virus fusion and enhance influenza virus" exact="respiratory disease." post="Sci Transl Med. 2013;5(200):200ra114. 6ZhouF, TrieuM�?C, DaviesR, CoxRJ. Improving"/>
 <result pre="disease. Sci Transl Med. 2013;5(200):200ra114. 6ZhouF, TrieuM�?C, DaviesR, CoxRJ. Improving" exact="influenza" post="vaccines: challenges to effective implementation. Curr Opin Immunol. 2018;53:88�?95.29719276"/>
 <result pre="effective implementation. Curr Opin Immunol. 2018;53:88�?95.29719276 7TregoningJS, RussellRF, KinnearE. Adjuvanted" exact="influenza" post="vaccines. Hum Vaccin Immunother. 2018;14(3):550�?564.29232151 8ZhaoK, ShiX, ZhaoY, et"/>
 <result pre="ZhaoY, et al. Preparation and immunological effectiveness of a swine" exact="influenza" post="DNA vaccine encapsulated in chitosan nanoparticles. Vaccine. 2011;29(47):8549�?8556.21945253 9Laliberté�?GagnéM�?È,"/>
 <result pre="13SinghSM, AlkieTN, NagyÉ, KulkarniRR, HodginsDC, SharifS. Delivery of an inactivated" exact="avian influenza" post="virus vaccine adjuvanted with poly(D, L�?lactic�?co�?glycolic acid) encapsulated CpG"/>
 <result pre="AlkieTN, NagyÉ, KulkarniRR, HodginsDC, SharifS. Delivery of an inactivated avian" exact="influenza" post="virus vaccine adjuvanted with poly(D, L�?lactic�?co�?glycolic acid) encapsulated CpG"/>
 <result pre="ChiocchettiA, DianzaniUExploiting PLGA�?based biocompatible nanoparticles for next�?generation tolerogenic vaccines against" exact="autoimmune disease." post="Int J Mol Sci. 201920(1):204. 15PatiR, ShevtsovM, SonawaneA. Nanoparticle"/>
 <result pre="a heat�?stable and orally delivered recombinant M2e�?expressing B subtilis spore�?based" exact="influenza" post="vaccine. Hum Vaccin Immunother. 2014;10(12):3649�?3658.25483702 25FerreiraL, FerreiraR, SchumannW. Bacillus"/>
 <result pre="LiuJ, et al. Intramuscular and intranasal immunization with an H7N9" exact="influenza" post="virus�?like particle vaccine protects mice against lethal influenza virus"/>
 <result pre="an H7N9 influenza virus�?like particle vaccine protects mice against lethal" exact="influenza" post="virus challenge. Int Immunopharmacol. 2017;2018(58):109�?116.s 39BrightRA, CarterDM, DanilukS, et"/>
 <result pre="virus�?like particles elicit broader immune responses than whole virion inactivated" exact="influenza" post="virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871�?3878.17337102 40KimM�?C, SongJ�?M, EunjuO,"/>
 <result pre="MorrisS, MaucourantS, et al. A virus�?like particle vaccine candidate for" exact="influenza" post="A virus based on multiple conserved antigens presented on"/>
 <result pre="influenza A virus based on multiple conserved antigens presented on" exact="hepatitis" post="B tandem core particles. Vaccine. 2018;36:873�?880.29306508 44GaoX, WangW, LiY,"/>
 <result pre="virus�?like particle vaccine broadly protects mice from multiple subtypes of" exact="influenza" post="a virus. MBio. 2015;6(4):1�?9. 46López�?MacíasC, Ferat�?OsorioE, Tenorio�?CalvoA, et al."/>
 <result pre="et al. Safety and immunogenicity of a virus�?like particle pandemic" exact="influenza" post="A (H1N1) 2009 vaccine in a blinded, randomized, placebo�?controlled"/>
 <result pre="JohnsonC, et al. Safety and immunogenicity of a recombinant M2e–flagellin" exact="influenza" post="vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29(32):5145�?5152.21624416 52TaoP, ZhuJ,"/>
 <result pre="2012;7(9):e45765.23029232 59DengL, IbañezLI, Van Den BosscheV, et al. Protection against" exact="influenza" post="a virus challenge with M2e�?displaying filamentous Escherichia coli phages."/>
 <result pre="et al. Safety and immunogenicity of a virus�?like particle pandemic" exact="influenza" post="A (H1N1) 2009 vaccine: Results from a double�?blinded, randomized"/>
 <result pre="evaluation of alginate�?coated chitosan and trimethylchitosan nanoparticles loaded with PR8" exact="influenza" post="virus for nasal immunization. Asian J Pharm Sci. 2020;14(2):216�?221."/>
 <result pre="adjuvant enhances the immunogenicity and cross�?protective efficacy of a pre�?pandemic" exact="influenza" post="A H5N1 vaccine in mice. Vaccine. 2012;30(2):254�?264.22085545 75HongDK, ChangS,"/>
 <result pre="2012;30(2):254�?264.22085545 75HongDK, ChangS, BothamCM, GiffonTD, FairmanJ, LewisDB. Cationic lipid/DNA complex�?adjuvanted" exact="influenza" post="a virus vaccination induces robust cross�?protective immunity. J Virol."/>
 <result pre="CallejoB, ChangS, et al. Cationic lipid/DNA complexes (JVRS�?100) combined with" exact="influenza" post="vaccine (Fluzone®) increases antibody response, cellular immunity, and antigenically"/>
 <result pre="ZeiraE, et al. Immunogenicity and safety of a novel liposomal" exact="influenza" post="subunit vaccine (INFLUSOME�?VAC) in young adults. J Med Virol."/>
 <result pre="YangCK, et al. Vaxfectin®, a cationic lipid�?based adjuvant for protein�?based" exact="influenza" post="vaccines. Vaccine. 2009;27(46):6399�?6403.19552895 79LasicDD. Novel applications of liposomes. Trends"/>
 <result pre="Biotechnol. 1998;16(7):307�?321.9675915 80AlmeidaJ, EdwardsDC, BrandC, HeathT. Formation of virosomes from" exact="influenza" post="subunits and liposomes. Lancet. 1975;306(7941):899�?901. 81StegmannT, MorseltHW, BooyFP, BreemenJF,"/>
 <result pre="1975;306(7941):899�?901. 81StegmannT, MorseltHW, BooyFP, BreemenJF, ScherphofG, WilschutJ. Functional reconstitution of" exact="influenza" post="virus envelopes. EMBO J. 1987;6(9):2651�?2659.3678202 82CryzSJ, QueJU, GlückR. A"/>
 <result pre="2000;43(2):197�?205.10967226 84HuckriedeA, BungenerL, StegmannT, et al. The virosome concept for" exact="influenza" post="vaccines. Vaccine. 2005;23:S26�?S38.16026906 85MoserC, AmackerM, KammerAR, RasiS, WesterfeldN, ZurbriggenR."/>
 <result pre="complex as a new formulation to induce intra�?subtypic protection against" exact="influenza" post="virus challenge. Antiviral Res. 2012;95(3):229�?236.22809863 87MischlerR, MetcalfeIC. Inflexal®V a"/>
 <result pre="Antiviral Res. 2012;95(3):229�?236.22809863 87MischlerR, MetcalfeIC. Inflexal®V a trivalent virosome subunit" exact="influenza" post="vaccine: production. Vaccine. 2002;20:B17�?B23.12477413 88LovgrenK, MoreinB. The requirement of"/>
 <result pre="adults comparing cell mediated and humoral immune responses induced by" exact="influenza" post="ISCOMTM vaccines and conventional vaccines. Vaccine. 2000;19(9–10):1180�?1187.11137255 95SambharaS, KurichhA,"/>
 <result pre="2000;19(9–10):1180�?1187.11137255 95SambharaS, KurichhA, MirandaR, et al. Heterosubtypic immunity against human" exact="influenza" post="A viruses, including recently emerged avian H5 and H9"/>
 <result pre="Gold nanoparticle�?M2e conjugate coformulated with CpG induces protective immunity against" exact="influenza" post="A virus. Nanomedicine (Lond). 2014;9(2):237�?251.23829488 103IngroleRS, TaoW, TripathyJN, GillHS."/>
 <result pre="Synthesis and immunogenicity assessment of elastin�?like polypeptide�?M2e construct as an" exact="influenza" post="antigen. Nano Life. 2014;4(2):1450004.25825595 104WangC, ZhuW, LuoY, WangBZ. Gold"/>
 <result pre="Life. 2014;4(2):1450004.25825595 104WangC, ZhuW, LuoY, WangBZ. Gold nanoparticles conjugating recombinant" exact="influenza" post="hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. Nanomedicine."/>
 <result pre="and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to" exact="hepatitis" post="B vaccine. Mol Pharm. 2011;8(2):405�?415. 21189035 111TanZ, LiuW, LiuH,"/>
 <result pre="Immunizations with heterosubtypic virus�?like particles elicit cross protection against divergent" exact="influenza" post="A viruses in mice. Sci Rep. 2018;8(1):11�?13.29311646 115PilletS, AubinÉ,"/>
 <result pre="AubinÉ, TrépanierS, et al. A plant�?derived quadrivalent virus like particle" exact="influenza" post="vaccine induces cross�?reactive antibody and T cell response in"/>
 <result pre="Immunogenicity and safety of a quadrivalent plant�?derived virus like particle" exact="influenza" post="vaccine candidate—Two randomized Phase II clinical trials in 18"/>
 <result pre="RomeijnS, KrosA, JiskootW. Adjuvant effect of cationic liposomes for subunit" exact="influenza" post="vaccine: Influence of antigen loading method, cholesterol and immune"/>
 <result pre="KünziV, et al. Eleven years of Inflexal® V—a virosomal adjuvanted" exact="influenza" post="vaccine. Vaccine. 2009;27(33):4381�?4387.19450630"/>
</results>
